Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia

Launched by MUHAMED AHMED ABDELMOATY MUHAMED ALHAGRASY · Jun 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying certain proteins and substances in the blood—called Antithrombin III, Protein C, Protein S, and D-dimer—in people with Acute Leukemia, which includes two main types: Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). The researchers want to see if the levels of these substances are different in patients with these types of leukemia compared to healthy people. Understanding these differences might help doctors learn more about how leukemia affects the blood and clotting.

People who have been diagnosed with either ALL or AML and are willing to join the study may be eligible to participate. Those with known blood clotting disorders or current blood clots will not be included. Participants will have a full medical check-up, blood tests to measure the proteins and other routine blood work, and a special test called flow cytometry that helps analyze blood cells. This is an observational study, so no treatment changes will be made, and the main goal is to gather information that could help improve care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. patients with leukemia in group 1 and 2.
• • 2. willing to participate in the study.
• Exclusion Criteria:
• • 1. refusing to participate.
• • 2. patients with know to have either hereditary thrombophilia or current thrombosis.